Long acting GLP-1 receptor agonist (injectable)
Exenatide (ITCA 650 implant) 20 ug implant continuous
EXENIMP_IMPLANT_20UG_CONT
Dose per day.
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 4.12 (0.18 to 143) | 0.22 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.21 (1.41 to 7.21) | 0.43 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.80 (1.01 to 14.39) | 0.39 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.75 (0.11 to 3.87) | 0.73 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.29 (0.53 to 24.92) | 0.29 |